In summary, measurement of intratumoral CD8+ T-lymphocyte and stroma fractions combined with conventional markers of prognosis (T and N stage, lymphatic and vascular invasion, identified on multivariate modeling) provides superior patient stratification for recurrence and survival for early stage CRC patients. This evidence concerns the gene CD8A and colorectal carcinoma.